PHCbi's LiCellMo Wins Prestigious R&D 100 Award for Innovation in Live Cell Analysis

The Biomedical Division of PHC Corporation has earned a 2025 R&D 100 Award for its revolutionary live cell metabolic pathway analyzer, LiCellMo®. Recognized as one of the most innovative technologies of the year by R&D World, LiCellMo offers continuous, real-time data on cellular metabolism, transforming how lab professionals monitor and optimize cell cultures.

Launched in Japan in September 2024 and rolled out to the U.S., UK, EU, China, and other Asian regions the following month, LiCellMo is specifically designed for research use. It provides unmatched visibility into live cell dynamics, aiding researchers in therapeutic development and decision-making.

Key Selling Points for Lab Professionals

• Real-time Monitoring: Continuously tracks glucose and lactate levels without disrupting the culture environment.

• Enhanced Reproducibility: Improves consistency and quality in cell and gene therapy manufacturing.

• Seamless Integration: Compatible with most CO2 incubators; installs with minimal workflow disruption.

• Proven Technology: Utilizes proprietary in-line monitoring from PHC's blood glucose sensors.

Unlike conventional sampling methods, which can miss critical metabolic changes and introduce contamination risks, LiCellMo provides precise, minute-by-minute insights. This makes it a must-have tool for labs working in cancer immunology, stem cell research, and CGT applications.

Chikara Takauo, Director of PHC Corporation and Head of the Biomedical Division, said, "We are deeply honored that LiCellMo has been recognized with an R&D 100 Award. This innovation empowers researchers with new insights into cell metabolism, particularly in cancer immunology and stem cell research, and supports the advancement of manufacturing processes for next generation therapies."